<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795768</url>
  </required_header>
  <id_info>
    <org_study_id>3689</org_study_id>
    <nct_id>NCT01795768</nct_id>
  </id_info>
  <brief_title>Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours</brief_title>
  <acronym>FGFR</acronym>
  <official_title>Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the activity of the FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2
      amplified breast, squamous lung and stomach cancer whose cancers have progressed following
      previous chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint

      - To assess anti-tumour activity as change in tumour size at 8 weeks and the correlation with
      change in tumour ERK1/2 phosphorylation at day 10-14.

      Secondary endpoints

        -  Objective response rate to AZD4547 in all patients and in each tumour group

        -  Safety and tolerability of AZD4547 in all patients

        -  Disease control rate at 8 weeks

        -  Progression free survival in all patients and in each tumour group
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess anti-tumour activity as change in tumour size at 8 weeks and the correlation with change in tumour ERK1/2 phosphorylation at day 10-14.</measure>
    <time_frame>Baseline (tumour size, pERK), day 14(pERK), and week 8(tumour size)</time_frame>
    <description>A primary objective of the study is to collect serial research biopsies at baseline and on treatment with AZD4547, to assess the molecular changes that occur in the tumour in response to AZD4547 treatment and correlate with change in tumour size assessed at 8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Eight weeks from treatment initiation and then every 6 weeks thereafter</time_frame>
    <description>Response rate is assessed using RECIST 1.1 radiological response and centrally reviewed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Time measured from baseline to disease progression or death from any cause (approximately 3-9 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate at eight weeks</measure>
    <time_frame>Disease control rate will be calculated as the proportion of patients with CR/PR/SD at eight weeks from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AZD4547</measure>
    <time_frame>Toxicity is assessed from consent until 30 days following treatment cessation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Oesophageal Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Lung</condition>
  <arm_group>
    <arm_group_label>Single Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD 4547</intervention_name>
    <arm_group_label>Single Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Female or male aged 25 years or older.

          -  Mandatory provision of archival or fresh tumour biopsy for confirmation of FGFR gene
             amplification.

          -  World Health Organisation performance status 0-2, minimum life expectancy of 12 weeks
             from proposed first dose date

          -  Patient ability to comply with the collection of tumor biopsies which is mandatory at
             baseline and on days 10-14

          -  Calcium and phosphate within normal limits.

          -  At least one lesion, not previously irradiated, that can be accurately measured at
             baseline as &gt;=10 mm in the longest diameter - except lymph nodes which must have short
             axis &gt;=15 mm.

          -  Local disease confined to the stomach or oesophagus is not considered measurable
             (patients with locally advanced gastro-oesophageal adenocarcinoma must have at least
             one measurable nodal lesion &gt;=15mm in the short axis).

        Tumour specific inclusion criteria

        Advanced gastro-oesophageal adenocarcinoma

          -  Histologically proven metastatic or locally advanced inoperable adenocarcinoma of the
             stomach, lower oesophagus or oesophago-gastric junction.

          -  Documented progression after 1 or 2 prior courses of chemotherapy for advanced
             disease,

          -  FGFR2 amplification

        Advanced breast carcinoma

          -  Histologically confirmed metastatic or locally advanced breast cancer, negative for
             HER2 as determined by local laboratory.

          -  Patients with locally advanced disease must have recurrent, or progressive, disease
             that is not suitable for treatment with curative intent

          -  Patients with ER positive disease must have been treated with at least one line of
             hormonal therapy for recurrent/progressive disease or have been on hormonal therapy at
             the time of recurrence/progression

          -  Documented progression after at least one and no more than three prior courses of
             chemotherapy for advanced disease.

          -  FGFR1 amplification

        Advanced squamous cell lung cancer

          -  Histologically confirmed metastatic or locally advanced squamous cell carcinoma of
             lung

          -  Documented progression after 1 or 2 prior courses of chemotherapy for advanced disease

          -  FGFR1 amplification

        Exclusion criteria

          -  Treatment potent inhibitors or inducers of CYP3A4, 2C8 or 2D6 or substrates of CYP3A4
             within specified durations prior to the first dose of study treatment

          -  Major surgery (excluding placement of vascular access) within 4 weeks before the first
             dose of study treatment

          -  Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a
             limited field of radiation for palliation within 2 weeks before the first dose of
             study treatment

          -  Prior exposure to AZD4547 or any other drug with FGFR inhibition as its primary mode
             of action

          -  Untreated brain metastases

          -  Inadequate bone marrow reserve or organ function

          -  Corrected total calcium &gt; ULN

          -  Total phosphate &gt; ULN

          -  Mean resting corrected QT interval &gt; 470 msec obtained from 3 consecutive
             electrocardiograms (ECGs)

          -  Any of the following ophthalmological criteria: 1)Current evidence or previous history
             of retinal pigmented epithelium detachment (RPED). 2)Previous laser treatment or
             intra-ocular injection for treatment of macular degeneration. 3) Current evidence or
             previous history of dry or wet age-related macular degeneration. 4) Current evidence
             or previous history of retinal vein occlusion (RVO). 5) Current evidence or previous
             history of retinal degenerative diseases (e.g. hereditary). 6) Current evidence or
             previous history of any other clinically relevant chorioretinal defect
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Gillbanks</last_name>
    <phone>+44(0)2086613156</phone>
    <email>angela.gillbanks@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Smyth, MB MRCP MSc</last_name>
    <phone>+44(0)2086613156</phone>
    <email>elizabeth.smyth@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London and Surrey</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Gillbanks</last_name>
      <phone>+44(0)2086613156</phone>
      <email>angela.gillbanks@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Cunningham, MD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Turner, MA MRCP PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjay Popat, BSc MBBS MRCP PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Smyth, MB MRCP MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non randomised</keyword>
  <keyword>Open label</keyword>
  <keyword>Multicentre</keyword>
  <keyword>Phase II biomarker study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

